What is it about?
Many research goes into developing cancer drugs daily, prostate cancer especially. In recent investigations, CREB-binding protein has been identified as a potential target for novel drugs in castration resistant prostate cancer. In one of these investigations, we came across a novel drug testified under in vivo and in vitro studies to possess therapeutic anti-cancer properties . Hence, we carried out an in silico experiment to confirm this result as well as identify the culprit behind this miracle.
Photo by Abbie Parks on Unsplash
Why is it important?
The use of computational tools in this research showed the interaction dynamics between the target and the novel drug. With this knowledge, the modality of pharmacodynamics and pharmacokinetics is best understood. Also, further attesting the novel drug to processed to clinical trials.
Read the Original
This page is a summary of: Exploring the Role of Asp1116 in Selective Drug Targeting of CREBcAMP- Responsive Element-binding Protein Implicated in Prostate Cancer, Combinatorial Chemistry & High Throughput Screening, May 2020, Bentham Science Publishers, DOI: 10.2174/1386207323666200219122057.
You can read the full text:
The following have contributed to this page